- Home
- CRGY vs RCKT Comparison
CRGY vs RCKT Comparison
Compare CRGY & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRGY | RCKT |
|---|---|---|
| Founded | 1986 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 534.2M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRGY | RCKT |
|---|---|---|
| Price | $12.18 | $4.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 14 |
| Target Price | $13.64 | ★ $29.65 |
| AVG Volume (30 Days) | ★ 8.4M | 2.7M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $3,579,782,000.00 | N/A |
| Revenue This Year | $26.77 | N/A |
| Revenue Next Year | N/A | $97.68 |
| P/E Ratio | $99.08 | ★ N/A |
| Revenue Growth | ★ 22.14 | N/A |
| 52 Week Low | $6.83 | $2.19 |
| 52 Week High | $12.40 | $8.80 |
Technical Indicators
Market Signals| Indicator | CRGY | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 64.07 | 53.84 |
| Support Level | $8.29 | $2.99 |
| Resistance Level | $12.40 | $5.39 |
| Average True Range (ATR) | 0.56 | 0.38 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 88.62 | 34.11 |
Price Performance
Historical ComparisonAbout CRGY Crescent Energy Company
Crescent Energy Co is an energy company committed to delivering value for shareholders through disciplined growth, acquisition ideas, and the consistent return of capital. Its long-life, balanced portfolio combines stable cash flows from low-decline production with deep, high-quality development inventory. The Company's investing and operating activities are focused in Texas and the Rocky Mountain region.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.